Chemo-immunotherapy for hairy cell leukemia

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Nucleoside analogs like cladribine and pentostatin have significantly improved hairy cell leukemia (HCL) treatment outcomes.
• Despite high initial response rates, a notable proportion of patients experience relapse, necessitating further therapeutic advancements.

Purpose of the Study:

• To review current and emerging treatment strategies for hairy cell leukemia (HCL).
• To discuss the role of minimal residual disease (MRD) detection in managing HCL.
• To explore predictive markers for relapse in HCL patients.

Main Methods:

• Review of existing literature on HCL treatment with nucleoside analogs.
• Analysis of novel therapeutic modalities including monoclonal antibodies and immunotoxins.
• Evaluation of techniques for minimal residual disease (MRD) detection, such as polymerase chain reaction (PCR) for immunoglobulin heavy chain variable region gene (IGHV) and multiparameter flow cytometry.

Main Results:

• Nucleoside analogs induce long-lasting remissions in most HCL patients, reducing the need for traditional treatments like splenectomy.
• Up to 40% of patients may not respond to initial therapy or may relapse within years.
• Emerging therapies like rituximab and BL22, alongside advanced MRD detection, show promise in managing HCL.

Conclusions:

• While nucleoside analogs are effective, further research is needed to address treatment resistance and relapse in HCL.
• Prospective randomized trials are required to validate the impact of new therapies and MRD eradication on relapse rates.
• Identifying patients at higher risk of relapse, potentially through pretreatment characteristics like IGHV mutational status, could personalize HCL treatment strategies.